世界の抗菌薬市場(2014-2024)...市場調査レポートについてご紹介

【英文タイトル】Antibacterial Drugs: World Industry and Market Prospects 2014-2024

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Executive Summary
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Research and Analysis Methods
2. Introduction to Antibacterials and Antibacterial Drugs
2.1 Bacterial Infections
2.1.1 How Bacteria Cause Infections
2.1.2 Classification of Bacteria
2.1.3 Types of Bacterial Infection
2.1.4 Leading Causative Bacterium
2.1.5 Incidence and Mortality Profiles for Common Bacterial Infection
2.2 Treating Infections
2.2.1 The History of Antibacterial Drug Development
2.2.2 Mechanisms of Action
2.2.3 Leading Classes of Antibacterial Compounds
2.2.3.1 Cephalosporins
2.2.3.2 Penicillins
2.2.3.3 Carbapenems
2.2.3.4 Fluoroquinolones
2.2.3.5 Macrolides
2.3 Antibacterial Drugs Resistance
3. Antibacterial Drugs: World Market, 2014-2024
3.1 Antibacterials Revenues Plateau between 2009 and 2013
3.1.1 Antibacterial Drugs – Market Segmentation
3.2 Antibacterial Market Forecast, 2014-2024: Decline in Revenues for Fluoroquinolones
3.2.1 Drivers and Restraints in the Antibacterial Market, 2014-2024
3.2.2 Generic Erosion and Prescription Control will Limit Market Growth
3.2.3 Changes in Sector Market Shares, 2014-2024
3.3 Pfizer is the Clear Leader in the Antibacterial Drugs Market
3.3.1 Pfizer Usurped by Cubist as the Leading Antibacterial Drug Manufacturer – Company Revenue Forecasts 2014-2024
3.3.2 Fragmented Market to Fracture Further
3.3.3 Leading Firms without Leading R&D Pipelines
4. Cephalosporin Market Forecast, 2014-2024
4.1 Cephalosporin Market 2012-2013 – No Dominant Brands
4.2 Late-Stage Cephalosporins to Gain Market Share Between 2014 and 2024
4.3 Basilea, Cubist, and Forest Labs to Lead Cephalosporin Market Between 2014 and 2024
4.3.1 Drivers and Restraints in the Cephalosporins Market, 2014-2024
4.3.2 Cephalosporins Lack Market Exclusivity
4.3.3 Strong Pipeline for Novel Cephalosporins
4.4 Rocephin (Roche) – The Only Treatment for Gonorrhoea in the US
4.4.1 Off Patent but not Forgotten
4.4.2 Declining Revenues Owing to Competition – Forecast 2014-2024
4.5 Sulperazon – India’s Leading Treatment for RTIs and UTIs
4.5.1 Continued Growth in the Emerging Markets, Revenue Forecast 2014-2024
4.6 Zinnat/Ceftin – GSK’s Established Cephalosporin
4.6.1 Continued Decline in Revenue – Forecast 2014-2024
4.7 Meiact – A Broad Range Community Antibiotic
4.7.1 Minor Spectracef Sales in the US Leads to Pass the Product
4.7.2 Competition in Japan to Hinder Growth – Revenue Forecast 2014-2024
4.8 Flomox – Shionogi’s Third-Generation Cephalosporin
4.8.1 Patent Issues and Litigation
4.8.2 Genericisation and Safety to Restrict Sales – Forecast 2014-2024
4.9 Zinforo/Teflaro (Ceftaroline Fosamil): The First of the Fifth-Generation Cephalosporins
4.9.1 Unmet Needs in Pneumonia to Drive Growth – Revenue Forecast 2014-2024
4.10 Zeftera (Ceftobiprole): Approved for Pneumonia in Europe
4.10.1 Future Sales Dictated by US Approval – Revenue Forecast 2014-2024
4.11 CXA-201 (Ceftrolozane-Tazobactam): The Next Blockbuster Antibacterial
4.11.1 Broad Label and Spectrum of Activity Leads to Rapid Uptake – Revenue Forecast 2014-2024
4.12 CAZ-AVI (Ceftazidime-Avibactam): Forest Labs to Enter the Market on Phase II Data
4.12.1 Competition from CXA-201 to Limit Sales – Forecast 2014-2024
5. Penicillin Market Forecast, 2014-2024
5.1 Generics and Augmenting Dominate the Penicillins Market in 2012 and 2013
5.2 Augmentin to lose its Dominance over the Coming 10 Years – Market Shares for Penicillin Drugs, 2014-2024
5.3 Penicillin Antibacterials: Market Forecast 2014-2024
5.4 Drivers and Restraints on the Penicillin Market 2014-2024
5.5 Augmentin – Blockbuster Facing Generic Competition
5.5.1 Augmentin Recalled in Asian and Middle Eastern Markets
5.5.2 Stable Revenues in Spite of Generic Competition
5.5.3 Revenue Forecast 2014-2024
5.6 Zosyn/Tazocin (Piperacillin-Tazobactam) – Pneumonia Therapeutic
5.6.1 Patent Expiry and Revenue Extension for Pfizer
5.6.2 Historic and Current Revenue Performance
5.6.3 Revenue Forecast 2014-2024
5.7 Unasyn – Gram-negative and Positive Antibiotic
5.7.1 Consistently Falling Revenues – Forecast 2014-2024
5.8 Amoxil (Amoxicillin) – A Historic Antibacterial Brand
5.8.1 Marginal Decline in Revenue – Forecast 2014-2024
5.9 Generic Amoxicillin
5.9.1 Revenue Forecast 2014-2024
5.10 Generic Amoxicillin-Clavulanic Acid
5.10.1 Revenue Forecast 2014-2024
6. Fluoroquinolone Market Forecast, 2014-2024
6.1 The Fluoroquinolone Market 2012-2013
6.2 Changing Market Share for Fluoroquinolone Antibacterials 2014-2024
6.3 Fluoroquinolone Antibacterial Drugs: Market Forecast 2014-2024
6.4 Trends in the Fluoroquinolone Market
6.4.1 Safety Fears for Fluoroquinolones
6.4.2 Avelox Patent Cliff
6.4.3 Inhaled Fluoroquinolone Formulations
6.5 Fluoroquinolone Market Forecast 2014-2024
6.6 Avelox
6.6.1 Safety Profile Hampers Sales
6.6.2 Generic Competition
6.6.3 Revenue Forecast 2014-2024
6.7 Cravit and Levaquin
6.7.1 Generic Competition Affecting Revenue Worldwide
6.7.2 Lifecycle Management for Cravit and Levaquin
6.7.3 Revenue Forecast 2014-2024
6.8 Vigamox
6.8.1 Branded and Generic Challenges 2009-2012
6.8.2 Moxeza: A Next-Generation Form of Vigamox
6.8.3 Revenue Forecast 2014-2024
6.9 Cirpodex and Cipro – Two Preparations of Ciprofloxacin
6.9.1 Ciprodex: A Second-Generation Ophthalmic Antibiotic
6.9.1.1 Revenue Forecast 2014-2024
6.9.2 Cipro Revenue Forecast 2013-2023: Continued Generic Erosion
6.10 Geninax
6.10.1 Revenue Forecast 2014-2024
6.11 Delafloxacin
6.11.1 Revenue Forecast 2014-2024
7. Macrolide Market Forecast, 2014-2024
7.1 Macrolide Market in 2012-2013
7.2 Changing Market Share for Macrolides, 2014-2024
7.3 Macrolide Antibacterials: Market Forecast 2014-2024
7.4 Trends in the Macrolide Market
7.5 Biaxin/Clarith
7.5.1 Revenue 2012-2013
7.5.2 Lifecycle Management for Continued Market Presence
7.5.3 Revenue Forecast 2014-2024
7.6 Zithromax
7.6.1 Concerns Over Safety and Marketing in the US
7.6.2 Effectiveness in Drug-Resistant Strains
7.6.3 Revenue Forecast 2014-2024
7.7 Dalacin
7.7.1 Revenue Forecast 2014-2024
7.8 Dificid
7.8.1 Rapid Uptake Slowed by High Cost
7.8.2 New Approvals and Expanded Indications
7.8.3 Revenue Forecast 2014-2024
7.9 Solit
7.9.1 Revenue Forecast 2014-2024
8. Carbapenem Market Forecast, 2014-2024
8.1 Carbapenem Market 2012-2013
8.2 Changing Market Share for Carbapenems, 2014-2024
8.3 Carbapenem Market Forecast, 2014-2024
8.4 Trends in the Carbapenem Market
8.4.1 Rising Prevalence of Carbapenemases and ?-Lactamases
8.4.2 No New Carbapenems in Late-Stage Trials
8.5 Merrem/Meropenem
8.5.1 Generics Affecting Revenue Worldwide
8.5.2 Revenue Forecast 2014-2024
8.6 Primaxin
8.6.1 Combination Therapy for Lifecycle Management
8.6.2 Historic and Current Revenues
8.6.3 Revenue Forecast 2014-2024
8.7 Invanz
8.7.1 Revenue Forecast 2014-2024
8.8 Doribax
8.8.1 Doribax in HAP and VAP
8.8.2 Lifecycle Management in Japan and the Rest of the World
8.8.3 Revenue Forecast 2014-2024
9. Other Antibiotic Drugs: Forecast, 2014-2024
9.1 The Market for Other Classes of Antibacterial Drugs
9.2 Changing Market Share for Fluoroquinolone Antibacterials 2014-2024
9.3 Other Antibacterials: Market Forecast, 2014-2024
9.4 Trends in the Other Classes of Antibacterial Drugs
9.4.1 New Oxazolidinones Will Drive Growth
9.4.2 New Drug Classes to Drive Submarket Growth to 2023
9.5 Zyvox – The Market Leading Antibacterial
9.5.1 MRSA Activity Driving Revenue Growth
9.5.2 Promise in Tuberculosis and Anthrax
9.5.3 Patents, Litigation, and Competition – When and Who Will Produce Generic Linezolid?
9.5.4 Flat Growth to Patent Expiry, Revenue Forecast 2014-2024
9.6 Cubicin – The Leading Brand for ABSSSIs
9.6.1 Revenue Boosted by Approvals Worldwide
9.6.2 Patents, Litigation and Deals – How Long Will Market Exclusivity Last?
9.6.3 Sustained Growth through to 2017, Revenue Forecast 2014-2024
9.7 Tygacil – A Tetracycline With Many Approved Indications
9.7.1 Concerns Limiting Revenue Potential
9.7.2 Competition from Safer Novel Therapies Restricts Growth, Revenue Forecast 2014-2024
9.8 TOBI/TOBI Podhaler – The Market Leading Inhaler for Cystic Fibrosis
9.8.1 Historic and Current Revenue Performance
9.8.2 Approvals and Launches in New Markets to Drive Revenue Growth
9.8.3 Competition to Limit Long-term Growth, Revenue Forecast 2014-2024
9.9 Solodyn – A Treatment for Severe Acne
9.9.1 Generic Competition and Lifecycle Management
9.9.2 Limited Potential for Dermatology, Revenue Forecast 2014-2024
9.10 Vibativ – Limited Potential for Novel Lipoglycopeptide
9.10.1 Astellas Ends its Collaboration with Theravance
9.10.2 Limited HAP Label in the US – Revenue Forecast 2014-2024
9.11 Sirturo – A New Option for Multi-Drug Resistant TB
9.11.1 Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Revenue Forecast 2014-2024
9.12 Tedizolid – Market Leading Follow-on to Zyvox?
9.12.1 Competition Increasing: Revenue Forecast 2014-2024
9.13 Oritavancin – An Antibiotic With a Novel PK Profile
9.13.1 Single Dose Differentiation to Deliver Market Share, Revenue Forecast 2014-2024
9.14 Dalbavancin – Competing in a Crowded Indication
9.14.1 Sustained Growth Over the Coming 10 Years, Revenue Forecast 2014-2024
9.15 Surotomycin – Cubist’s Second Treatment for C. difficile
9.15.1 Delayed Launch to Limit Potential, Revenue Forecast 2014-2024
9.16 Nemonoxacin – Taiwan’s Global Antibacterial Drug
9.16.1 Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2014-2024
10. The Leading National Markets, 2014-2024
10.1 The US and China Dominate the Global Antibacterial Market, But For Different Reasons
10.2 Above-Average Growth in US: Regional Forecasts, 2014-2024
10.3 China to Slump in Market Share, While Brazil and India Push on
10.4 Incidence of Infection by Country, 2013
10.4.1 Incidence of Pneumonia in National Markets – Pneumonia Predominant in America
10.4.2 Incidence of Community Acquired Urinary Tract Infections in National Markets – High Incidence Rate in the UK, US, and Spain
10.4.3 Incidence of Bacterial Skin and Skin Structure Infections in National Markets – Massive Potential in the US
10.4.4 Incidence of Upper Respiratory Tract Infections in National Markets – Europe Leads the Way
10.5 Antibacterial Drug Consumption by Nation, 2013
10.5.1 Antibacterial Drug Consumption in the Major National Markets
10.5.2 Antibacterial Drug Consumption in Minor National Markets
10.6 The Antibacterials Market in the US
10.6.1 The Continued Dominance of the US Market
10.7 The European Union the Second Largest Regional Market
10.7.1 Marginal Expansion in Antibacterial Spending – Market Forecast 2014-2024
10.7.2 Action to Encourage Antibacterial Drug Development in the EU
10.7.3 Italians Continue to Lead the Way in Antibiotic Use
10.7.4 The French Fascination with Expensive Antibacterial Drugs
10.7.5 Germany – Europe’s Antibiotic Steward
10.7.6 The Rising Use of Antibacterials Drugs Within the UK
10.7.7 Spanish Antibacterial Market to Grow Between 2018 and 2024
10.8 Japan – Still the Third Largest National Market
10.8.1 The Pause Before Growth in the Japanese Market
10.9 Will South Korea Continue Its High Use of Antibiotics?
10.10 BRIC Nation Sales Still Expanding – Market Forecast 2014-2024
10.11 Chinese Antibacterial Market Bloated by Reported Overuse
10.11.1 Developing Antibacterials in China, for China
10.11.2 Government Controls Subdue Recent Growth – Market Forecast 2014-2024
10.12 Indian Market to Expand by 50% Over the Coming Decade
10.12.1 Restricting Antibiotic Use in India
10.12.2 Sustained Expansion of the Indian Market, Forecast 2014-2024
10.13 Brazilian Antibacterial Market to Double in Size
10.13.1 Brazilian Market to Be Driven by Drug Resistance
10.14 Russia, TB Explosion to Drive Growth – Forecast 2014-2024
11. The Antibacterial Drug R&D Pipeline in 2014
11.1 Gram-Positive vs. Gram-Negative
11.2 A Pipeline Dominated by Small Molecule Drugs
11.3 Leading Phase III Pipeline Candidates Treatments
11.3.1 Ceftolozane-Tazobactam – Future Gram-Negative Blockbuster
11.3.2 Ceftazidime-Avibactam – Skipping Phase III Trials
11.3.3 Surotomycin – Broad C. difficile Treatment to Reduce Relapse
11.3.4 Tedizolid – More Potent Than Zyvox with Fewer Doses?
11.3.5 Oritavancin – Differentiated by Dosing
11.3.6 Delafloxacin – A Leading pH Activated, Broad Spectrum Fluoroquinolone
11.3.7 Dalbavancin – A Pharmacoeconomic Proposition
11.3.8 Solithromycin – A Fluroketolide Without the Side-Effects
11.3.9 Finafloxacin – A Second pH Activated Fluoroquinolone with Broad Spectrum Activity
11.3.10 Eravacyline – Treating Gram-Negative cUTIs and cIAIs
11.3.11 Plazomicin – Straight to PIII in Carbapenem Resistant Infections
11.3.12 Cadazolid: Largest PIII C. Difficile Trial
11.4 Leading Phase II Antibacterial Drug Candidates
11.4.1 AZD5847: An Oxazolidinone for TB
11.4.2 Avarofloxacin is Still Waiting for a Partner
11.4.3 MK-7655 and Invanz – A Novel ?-Lactamase Combination
11.4.4 Omadacycline – Another Phase III Ready Partnership
11.4.5 Radezolid – On Melinta’s Back-Burner for Now
11.4.6 AFN-1252: Highly Specific S. Aureus Antibacterial
11.4.7 Sutezolid – Sequella Looking to Combine TB Treatments
11.4.8 Taksta (Fusidic acid) – Cempra’s Second Pipeline Candidate
11.4.9 TD-1792 – A Russian Antibacterial
11.4.10 Brilacidin – A Novel Peptide Antibacterial Agent
11.4.11 POL7080 – Polyphor and Roche in Multi-Million Dollar Deal
11.4.12 BC-3781- Unique Mechanism of Action at 23S?
11.5 Inhaled Antibiotics – Advantages in Lung Infections
11.5.1 Cayston: Competition for Novartis?
11.5.2 ARIKACE – Targeting P. aeruginosa
11.5.3 Aeroquin – Better than Podhaler?
11.5.4 BAYQ3939 – Cystic Fibrosis? Not Anymore
11.5.5 NKTR-061: Targeting Intubated Pneumonia
11.5.6 Pulmaquin: A Second Ciprofloxacin Candidate
11.5.7 AeroVanc Targets MRSA Infections
11.5.8 Inhaled Amikacin-Fosfomycin – Adjunctive Therapy for VAP
11.6 Biologics – Truly Novel Antibacterial Therapeutics
11.6.1 MK-3415A: First Antibacterial mAb to the Market?
11.6.2 KB001A – The Leading Antibody Against P. aeruginosa
11.6.3 Aridis Pharmaceuticals: Targeting P. aeruginosa and S. aureus
11.6.4 MEDI4893 – Early Stage mAb to S. Aureus
12. Qualitative Analysis of the Antibacterials Market, 2014
12.1 SWOT Analysis: Strengths, Weaknesses, Opportunities, and Threats within the Antibacterial Drug Market
12.2 STEP Analysis: Social, Technological, Economic, and Political Factors Affecting the Antibacterial Drug Industry and Market
12.2.1 Social Factors
12.2.2 Technological Developments
12.2.3 Economic Pressures
12.2.4 Political Issues
12.3 Market is Well Established and Demand will Remain Strong
12.4 High Prevalence of Infection Worldwide
12.5 Worldwide Demand for Antibacterials Drugs
12.6 Animal Models of Infection are Highly Predictive Compared with Other Therapeutic Areas
12.7 Cutting Into a Saturated Market
12.8 Superior Benefit over Generics?
12.9 Resistance – Nature’s Patent Expiry
12.10 Acute Treatment Limits Commercial Potential
12.11 Did Big Pharma Back Away from Antibacterial Drugs?
12.12 Resistance Will Continue to Present New Targets
12.13 First Biologic Antibacterials
12.14 Potential for Smaller Firms to Capitalise
12.15 Developing Preventative Vaccines Rather Than Treatments
12.16 Antibacterial Stewardship Reduces Usage
12.17 Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
12.17.1 Therapeutic Success in European Clinical Trials
12.17.2 Poor Primary End Points in FDA Guidelines
12.18 Reduction in Hospital Infection Rates – Reducing Demand for Antibacterial Drugs
12.19 Enticing Antibacterial Drug Discovery – Push and Pull Incentives
12.19.1 GAIN act: Post-Development Pull Incentives in the US
12.19.2 ADAPT – Building on the GAIN act
12.19.3 EMA Update Guideline – Streamlining Clinical Trials in the EU
12.19.4 Push Incentives for Antibacterial Drug Discovery with Public Funding
12.19.5 IMI: Public-Private Collaboration with GSK and AstraZeneca
12.19.6 Public Finance Pumping Money into Antibacterial Development
13. Research Interviews from Our Survey
13.1 Interview with Dr Vu Truong, Founder & CSO, Aridis Pharmaceuticals, United States
13.1.1 Opportunities for Antibacterial Monoclonal Antibodies
13.1.2 Positioning Monoclonal Antibacterials in the Clinic
13.1.3 Differentiating Factor for Biological Antibacterials
13.1.4 Hazard Pitfalls in Clinical Development
13.1.5 Trends in Antibacterial Drug Market – Novel Targets Rewarded
13.1.6 The Commercial Hazard of Acute Therapeutics
13.1.7 Progress from Government Incentives, But More to Come on the Manufacturing Side
13.1.8 Bacteriophages, Potentially Innovative Therapeutics
13.2 Interview with Lyn Baranowski and Sue Cammarata, Melinta Therapeutics, United States
13.2.1 Opportunities in Treating Skin Infections and Gonorrhoea
13.2.2 Superior Effect in Overweight Populations
13.2.3 Focussing on the Domestic US Market
13.2.4 Anionic Activity Opens up Possibilities in treating cUTIs and cIAIs
13.2.5 Superiority Means Uptake Won’t be Restricted
13.2.6 Clear Regulatory Guidance Clears Paths to Development
13.3 Interview with Tetraphase Pharmaceuticals
14. Antibacterial Drugs Market to 2024: Conclusions
14.1 Three Blockbuster Antibacterials in 2013, Leading Brands of 2013
14.2 The Leading Branded Antibacterial Drugs in 2024
14.3 Signs of Life in the Antibacterial Pipeline
14.4 Stemming the Tide of Antibacterial Drug Resistance
14.5 The Changing Face of Antibacterial Clinical Development


【レポート販売概要】

■ タイトル:世界の抗菌薬市場(2014-2024)
■ 英文:Antibacterial Drugs: World Industry and Market Prospects 2014-2024
■ 発行日:2014年3月
■ 調査会社:visiongain
■ 商品コード:Visiongain-4052642
■ 調査対象地域:グローバル
  • ビスフェノールAの世界市場2016-2020
    About Bisphenol-A The global Bisphenol A market considers the marketplace for the production, sale, and the distribution of the chemical compound Bisphenol A, a product primarily derived by the condensation reaction of phenol and acetone is a commercially valuable product. It has widespread supply chain impacts on many upstream and downstream industries such as those pertaining to plastics. Techna …
  • バイオ・ポリエチレンテレフタレートの世界市場
    The report covers the global bio-polyethylene terephthalate market that is segmented on the basis of application and geography. The global bio-polyethylene terephthalate market was valued at $457.9 million in 2014, and is projected to reach $1,317.5 million by 2019, at a CAGR of 23.5% from 2014 to 2019. The global bio-polyethylene terephthalate market has been analyzed based on the current proceed …
  • SandRidge Energy, Inc.:石油・ガスの開発・生産動向及びコスト分析- Q2, 2013
    SandRidge Energy, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary SandRidge Energy, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential sour …
  • 粘着テープの世界市場2016-2020
    About Adhesive Tapes Adhesive tapes stick to substances when pressure is applied, without the need for solvent, heat, or any other activator. Adhesives are coated on these tapes, either on one side or both sides. Many variants like single-sided, double-sided, adhesive transfer or transfer adhesive, single-coated, double-coated, carton sealing, masking, electrical and electronics are available in t …
  • 世界の印刷用紙&筆記用紙市場:種類別、地域別
    Global Printing and Writing Paper Market: About this market Technavio’s printing and writing paper market analysis considers sales from both printing paper and writing paper types. Our study also finds the sales of printing and writing paper in APAC, Europe, MEA, North America, and South America. In 2019, the printing paper segment had a significant market share, and this trend is expected to cont …
  • 世界のSkincare市場:M&A動向(2014年4月)
    Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global skincare market during April 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global skincare market throughout the month. Additionally, the report provides an overview of all the partneri …
  • 医療用複合材料の世界市場:繊維複合材、高分子・金属複合材、高分子・セラミック複合材
    About Medical Composite Materials Medical composite materials are used in place of steel, plastic, and aluminum for the manufacture of customized and complex products like advanced orthopedic devices, prosthetics, and body implants. They are also used in dental applications such as restoration and filling of natural teeth. These materials offer the following benefits: • High strength-to-weight rat …
  • 下咽頭癌:世界の臨床試験レビュー(2014年上半期)
    Hypopharyngeal Cancer Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Hypopharyngeal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hypopharyngeal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hypopharyngeal Cancer. It includes an overview of the trial numbers and the …
  • 教育用電子機器の世界市場:デスクトップ、ノートPC、タブレットPC、プロジェクター、サウンド・システム、電子黒板
    About Education Hardware Digitization of education has resulted in trends such as online learning and open education, which emphasize the strong role of technology in the education sector. Growing competition has led to a rise in the standards of education. As a result, educational institutions have adopted digital learning and are using desktops, projectors, and sound systems to enhance the learn …
  • 核燃料の世界市場
    ABSTRACTAbout Nuclear Fuels Nuclear fuel is a substance used to initiate and sustain a nuclear fission reaction in nuclear power stations to generate heat. This heat powers turbine to produce usable electrical energy. A nuclear reactor is a structure in which fissile material undergoes a controlled, self-sustaining nuclear reaction with simultaneous release of energy, which can be used to generate …
  • 世界の仮想発電所市場2015
    The Global Virtual Power Plants Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Virtual Power Plants industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Virtual Power Plants market analysis is provided for the international markets including develop …
  • 未熟児網膜症(Retinopathy Of Prematurity):世界の治験レビュー2014年下半期版
    Retinopathy Of Prematurity Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Retinopathy Of Prematurity Global Clinical Trials Review, H2, 2014" provides data on the Retinopathy Of Prematurity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Retinopathy Of Prematurity. It includes an overview of the t …
  • オートバイ用トランスミッションコントロールユニットの世界市場2019-2023
    Global Motorcycle Transmission Control Unit Market: About this market Motorcycle transmission control unit controls the modern electronic automatic and semi-automatic transmission system in motorcycles. Technavio’s motorcycle transmission control unit market analysis considers sales from both the segments, including single-clutch transmission and dual-clutch transmission. Our analysis also conside …
  • 溶接用呼吸用保護具の世界市場2017-2021
    ABSTRACTAbout Welding Respiratory Systems Welding is among several key application areas of respiratory protective equipment. Workers in the welding industry including welders, solderers, and brazers are exposed to various occupational hazards such as intense visible light and harmful radiation, burns, sparks, and airborne particulate matter. In addition, workers face risks such as lung cancer, ch …
  • 粒径分析の世界市場:レーザー回折、DLS(動的光散乱)、撮像(動的、静的)、コールター原理、NTA(ナノ粒子追尾解析)
    Particle size analysis or particle size measurement is a technique to determine the size and shape of the particles in the liquid or powder sample. Particle size analyzers are extensively used in formulating and manufacturing of products in several industries such as pharmaceuticals, chemicals & petroleum, mining, minerals & cement, and food & beverage, among others. The particle size analysis mar …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。